Lyell Immunopharma, Inc. (LYEL) 股票分析

公司概述

Lyell Immunopharma, Inc. operates as a clinical-stage cell therapy company dedicated to developing chimeric antigen receptor (CAR) T-cell product candidates specifically for patients suffering from hematologic malignancies and solid tumors. The company functions within the healthcare sector and the biotechnology industry, positioning itself to address high-need areas of oncology through advanced cellular immunotherapy technologies. With a market capitalization of $556.38M and annual revenue of $36,000, the enterprise currently employs a workforce count listed as N/A within its operational structure. The substantial disparity between the market cap of $556.38M and the minimal revenue of $36,000 indicates that the company's valuation is primarily driven by the potential of its pipeline assets, such as rondecabtagene autoleucel, rather than current financial performance or established commercial sales.

财务健康

The company reported revenue of $36,000 and net income of $-274,448,000 for the trailing twelve months, while EBITDA stood at $-186,746,000, revealing a cost structure where expenses significantly outweigh the negligible revenue stream. Free cash flow was recorded at $-81,467,128, which signifies a consumption of cash reserves necessary to fund ongoing research and development activities rather than generating capital returns. The gross margin is listed at 100.0%, reflecting the standard accounting treatment for clinical-stage entities with no cost of goods sold prior to commercialization, whereas the operating margin of -1024633.3% and profit margin of 0.0% highlight severe operational inefficiencies relative to the tiny revenue base due to high fixed costs. Total cash holdings of $247.22M exceed total debt of $50.99M, resulting in a debt-to-equity ratio of 20.55, suggesting a balance sheet that is leveraged by debt but comfortably covered by available liquidity. The current ratio of 5.28 indicates strong short-term liquidity, demonstrating that the company holds more than five times the value of its current liabilities in current assets. Return on equity is -87.0% and return on assets is -29.8%, metrics that reveal that management has not yet generated positive returns on the capital invested in the business due to the pre-revenue stage of operations.

估值评估

The trailing P/E ratio is N/A due to negative earnings, while the forward P/E is -28.39, implying that the market is pricing in a recovery or turnaround scenario where future earnings are expected to turn positive from current negative levels. The price-to-book ratio stands at 2.04, indicating that the market values the company at a 104% premium over its book value, reflecting investor confidence in the underlying intellectual property and pipeline potential despite current losses. The price-to-sales ratio is an extreme 15455.06, and the EV/EBITDA is -1.93, suggesting that traditional valuation multiples are not applicable and that value is derived from the probability of future commercial success rather than current profitability or sales volume. The 52-week high is $45.00 and the 52-week low is $7.65, meaning the stock is trading within a wide volatility range that encompasses significant downside risk and upside potential relative to the low point. The beta value is -0.07, which is an anomalous metric indicating that the stock price has moved inversely to the broader market or that the calculation reflects a lack of correlation with standard market indices.

Growth & Income

Revenue growth year-over-year is -45.5% and earnings growth year-over-year is N/A, illustrating a contraction in top-line sales which is typical for companies transitioning from early-stage development to clinical trials or commercial launch phases. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it retains all earnings, if any, to reinvest into growth initiatives such as clinical trials and regulatory filings. The negative revenue growth combined with a zero payout ratio confirms that the company is in a capital-intensive growth phase where all financial resources are directed toward product development rather than shareholder distributions. The overall growth and income profile is characterized by negative current expansion rates and a complete absence of dividend income, relying entirely on the successful advancement of its lead product candidates to drive future value creation.